Bevacizumab
Concept
Vocabulary Service
Overview
subject area of
-
A Distinct Advantage to Intraarterial Delivery of 89Zr-Bevacizumab in PET Imaging of Mice With and Without Osmotic Opening of the Blood–Brain Barrier Academic Article
-
A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial Academic Article
-
A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer Academic Article
-
A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: An analysis of the ATHENA trial Academic Article
-
Adjuvant Chemotherapy With or Without Biologics Including Antiangiogenics and Monoclonal Antibodies Targeting EGFR and EpCAM in Colorectal Cancer: A Systematic Review and Meta-analysis Academic Article
-
Adverse Gastrointestinal Events with Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors: Nested Case–Control Study Academic Article
-
Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study Academic Article
-
Aqueous Humor Cytokines and Long-Term Response to Anti–Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema Academic Article
-
Bevacizumab in advanced lung cancer: in search of the right drug for the right patient. Academic Article
-
Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial Academic Article
-
Canadian expert consensus: optimal treatment of neovascular age-related macular degeneration Academic Article
-
Changes in plasma hormones and heart rate variability in patients receiving the cardiotoxic anti-cancer agent bevacizumab Academic Article
-
Displacement Affinity Release of Antibodies from Injectable Hydrogels Academic Article
-
Dynamic Angiogenic Switch as Predictor of Response to Chemotherapy-Bevacizumab in Patients With Metastatic Colorectal Cancer Academic Article
-
Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme Academic Article
-
Final overall survival results and effect of prolonged (≥1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial Academic Article
-
First-Line Bevacizumab-Containing Therapy for Triple-Negative Breast Cancer: Analysis of 585 Patients Treated in the ATHENA Study Academic Article
-
First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients Academic Article
-
Increased incidence of retinopathy of prematurity and evolving treatment modalities at a Canadian tertiary centre Academic Article
-
MRI and 18FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial Academic Article
-
Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials Conference Paper
-
Metastatic renal cell cancer treatments: An indirect comparison meta-analysis Academic Article
-
Overstated Conclusions of a Pooled Analysis of Bevacizumab in Colon Cancer Academic Article
-
Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial Academic Article
-
Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: A phase II trial Academic Article
-
Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma Academic Article
-
Role of anti-vascular endothelial growth factor in the management of non-proliferative diabetic retinopathy without centre-involving diabetic macular oedema: a meta-analysis of trials Academic Article
-
Safety of bevacizumab in metastatic breast cancer patients undergoing surgery Academic Article
-
Same-Day Bilateral Intravitreal Anti-Vascular Endothelial Growth Factor Injections: Experience of a Large Canadian Retina Center Academic Article
-
Seasonal and Environmental Variations in Endophthalmitis after Intravitreal Anti-vascular Endothelial Growth Factor Injection: A Six-year Review Academic Article
-
Selective binding of C-6 OH sulfated hyaluronic acid to the angiogenic isoform of VEGF165 Academic Article
-
Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial Academic Article
-
Stroke Rates after Introduction of Vascular Endothelial Growth Factor Inhibitors for Macular Degeneration: A Time Series Analysis Academic Article
-
Targeted therapy for metastatic renal cell carcinoma Academic Article
-
The 12- and 24-Month Effects of Intravitreal Ranibizumab, Aflibercept, and Bevacizumab on Intraocular Pressure Academic Article
-
The evolution of immune checkpoint inhibitor combinations in advanced hepatocellular carcinoma – A systematic review Academic Article
-
Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline Academic Article
-
Treat‐and‐extend regimens of anti‐vascular endothelial growth factor therapy for retinal vein occlusions: a systematic review and meta‐analysis Academic Article
-
Using bevacizumab to treat metastatic cancer: UK consensus guidelines Academic Article